Enspryng (Satralizumab)

  • Brand Name: Enspryng
  • Innovator Brand Name: Enspryng
  • API: Satralizumab
  • Dosage Form: 1 Vial (Per Box)
  • Strength: 120mg/mL
  • Manufacturer Name: Hoffmann-La Roche Ltd
Get Price

Description

Enspryng Medication

Enspryng (Satralizumab) is an interleukin-6 (IL-6) receptor antagonist used for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Dosage: The recommended loading dosage of Satralizumab for the first three administrations is 120 mg by subcutaneous injection at 0, 2, & 4 Weeks, followed by a maintenance dosage of 120 mg every 4 weeks. Prior to every use of Satralizumab, advise patients to consult with their health specialist in case they suspect an active infection, including localized infections. In case of active infection, delay the use of Satralizumab until the infection is resolved.

Side Effects: The most commonly reported enspryng side effects (incidence at least 15%) include:

  • Headache
  • Gastritis
  • Rash
  • Arthralgia
  • Extremity pain
  • Fatigue
  • Nausea
  • Nasopharyngitis
  • Upper respiratory tract infection

Warnings and Precautions:

  • The enspryng uses are restricted in patients with known hypersensitivity to satralizumab or any of the inactive ingredients, active Hepatitis B infection, or active/untreated latent tuberculosis.
  • Live or live-attenuated vaccines should not be administered concurrently with enspryng dosing because clinical safety has not been established.
  • The ALT and AST levels should be monitored every 4 weeks for the initial three months of therapy, followed by every three months for one year.
  • Neutrophil counts should be monitored 4-8 weeks after initiation of therapy with satralizumab injection, and thereafter at regular clinically determined intervals.

More info

Storage: Refrigerate at 2°C-8°C (36°F-46°F) in original carton in order to protect from light. Neither freeze nor shake Satralizumab. Prior to administration, Satralizumab, if unopened, can be removed from and returned to the refrigerator, in case necessary. The total combined time out of refrigeration should not exceed 8 days at a temperature that does not exceed 30°C (86°F). Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the ENSPRYNG at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the ENSPRYNG Injections. Buying Procedure: In order to buy ENSPRYNG, you can contact us at our TOLL-FREE Number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: info@theindianpharma.com along with the legitimate ID Proof, standard Prescription and Medical Reports. Conclusions: Satralizumab Injection appears to be safe and effective as monotherapy or along with an immunosuppressant for patients with NMOSD and has the potential to become a valuable treatment option for these patients.

FAQ

What is Enspryng 120 mg? Enspryng 120 mg is a humanized monoclonal antibody medicine that is introduced to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. How is Satralizumab administered? Satralizumab is administered via subcutaneous injection only, with recommended sites of injection in the thigh and abdomen. What does Enspryng contain as an active substance? The medication Enspryng specifically contains the active substance Satralizumab. How much does enspryng cost? The enspryng price in India usually can vary depending on the wholesaler/pharmacy you visit. Enspryng is available as a brand name drug only, a generic version is not yet available. What is the best price for Satralizumab? Please contact Toll-free: +91 1800 889 1064|+919310090915 for satralizumab price in India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements. Can I get Enspryng (Satralizumab-mwge) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Enspryng (Satralizumab-mwge), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

×